Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CagriSema in type 2 diabetes with overweight/obesity
NCT05394519Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) and obesity comparing CagriSema with Placebo (2 arms). Primary endpoints: Relative change in body weight at 68 weeks and Achievement of greater than or equal to 5% weight reduction at 68 weeks. Started Feb 2023; status: completed.
02
Drugs
CagriSema
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT05394519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394519.